{"id":20676,"date":"2021-03-22T15:59:35","date_gmt":"2021-03-22T15:59:35","guid":{"rendered":"http:\/\/prrscontrolidiomas.advertis.es\/1-tipos-de-vacunas-frente-al-prrs\/"},"modified":"2021-03-26T10:13:05","modified_gmt":"2021-03-26T10:13:05","slug":"tipos-de-vacunas-frente-al-prrs","status":"publish","type":"page","link":"https:\/\/prrscontrol.com\/es\/vacunacion-prrs\/tipos-de-vacunas-frente-al-prrs\/","title":{"rendered":"1<\/span> Tipos de vacunas frente al PRRS"},"content":{"rendered":"

[vc_row][vc_column width=\u00bb1\/1″][vc_column_text el_class=\u00bbintro\u00bb]Actualmente, existen alrededor de 30 vacunas, algunas de ellas est\u00e1n disponibles solo en\u00a0su pa\u00eds de origen.<\/p>\n

Pr\u00e1cticamente todas ellas est\u00e1n basadas en virus atenuado (modified live\u00a0virus<\/strong>; MLV) o en virus inactivado<\/strong> (killed virus; KV) para PRRSV1 o PRRSV2, con la excepci\u00f3n\u00a0de dos vacunas de PRRSV2 basadas en subunidades. A d\u00eda de hoy, las vacunas que m\u00e1s se\u00a0utilizan en el campo son las MLV.[\/vc_column_text][vc_column_text]Desafortunadamente, las vacunas existentes tienen una eficacia limitada, ya que no\u00a0otorgan protecci\u00f3n completa y\/o universal.<\/p>\n

En general, las vacunas comerciales ofrecen\u00a0una buena protecci\u00f3n cl\u00ednica y virol\u00f3gica frente a un desaf\u00edo gen\u00e9ticamente hom\u00f3logo.\u00a0Sin embargo, su eficacia frente a cepas heter\u00f3logas es muy variable<\/strong>.[\/vc_column_text][vc_column_text]La industria farmac\u00e9utica y los centros de investigaci\u00f3n dedican grandes esfuerzos en\u00a0desarrollar vacunas contra el virus.<\/p>\n

Sin embargo, las vacunas experimentales (vectores\u00a0recombinantes que expresan prote\u00ednas del virus, vacunas ADN o vacunas basadas en\u00a0subunidades, por nombrar tan s\u00f3lo algunos ejemplos), no son capaces de superar ni las\u00a0estrategias que usa el virus para escapar de la inmunidad ni el inconveniente que supone\u00a0su elevada diversidad gen\u00e9tica. Por tanto, se considera que la eficacia de dichas vacunas\u00a0es como mucho equiparable a las de las MLV.[\/vc_column_text][vc_column_text el_class=\u00bbdestacado\u00bb]<\/p>\n

Ya sea en una granja concreta o en una regi\u00f3n, el manejo, la bioseguridad, la monitorizaci\u00f3n y la vacunaci\u00f3n son los pilares en los que debe apoyarse un plan de control de PRRS.<\/strong><\/p><\/blockquote>\n

[\/vc_column_text]

\"\"<\/a><\/div>
\"\"<\/a><\/div>[vc_column_text]<\/p>\n

Propiedades que deber\u00eda tener la vacuna ideal de PRRS:<\/h3>\n
    \n
  • R\u00e1pida inducci\u00f3n de una inmunidad de larga duraci\u00f3n.<\/li>\n
  • Protecci\u00f3n cruzada frente a un amplio rango de cepas, o cuanto menos frente a\u00a0aquellas m\u00e1s prevalentes en la regi\u00f3n.<\/li>\n
  • Necesidad de pocas dosis.<\/li>\n
  • Baja o nula excreci\u00f3n y transmisi\u00f3n del virus vacunal.<\/li>\n
  • IVA (Differentiate Infected from Vaccinated Animals). Diferenciaci\u00f3n entre animales\u00a0infectados y vacunados.<\/li>\n
  • Poder asegurar el cumplimiento de la administraci\u00f3n (compliance).<\/li>\n
  • Otros: que no sea cara, con pocos efectos adversos, f\u00e1cil de administrar, segura,\u00a0de dosis \u00fanica, etc.<\/li>\n<\/ul>\n

    [\/vc_column_text][vc_column_text el_class=\u00bbaviso\u00bb]<\/p>\n

    \n

    \u00a9 Laboratorios Hipra, S.A. 2026. Reservados todos los derechos.
    \nNinguna parte de este sitio web o cualquiera de sus contenidos puede ser reproducida, copiada, modificada o adaptada, sin el consentimiento previo por escrito de HIPRA.<\/p>\n

    [\/vc_column_text][\/vc_column][\/vc_row][vc_row top_padding=\u00bb30″ row_id=\u00bbreferencias\u00bb][vc_column width=\u00bb1\/1″]

    <\/i>Referencias<\/div>

    \n

      \n
    • Bautista EM, Molitor TW. Cell-mediated immunity to porcine reproductive and respiratory syndrome virus in swine. Viral Immunol. 1997, 10: 83-94.<\/li>\n
    • Bautista EM, Molitor TW. IFN gamma inhibits porcine reproductive and respiratory syndrome virus replication in macrophages. Arch Virol. 1999, 144:1191-200.<\/li>\n
    • Butler JE, Lager KM, Golde W, Faaberg KS, Sinkora M, Loving C, Zhang YI. Porcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic. Immunol Res. 2014, 59:81-108.<\/li>\n
    • Darwich L, D\u00edaz I, Mateu E. Certainties, doubts and hypotheses in porcine reproductive and respiratory syndrome virus immunobiology. Virus Res. 2010, 154:123-32.<\/li>\n
    • D\u00edaz I, Darwich L, Pappaterra G, Pujols J, Mateu E. Different European-type vaccines against porcine reproductive and respiratory syndrome virus have different immunological properties and confer different protection to pigs. Virology. 2006, 351:249-59.<\/li>\n
    • D\u00edaz I, Gimeno M, Darwich L, Navarro N, Kuzemtseva L, L\u00f3pez S, Galindo I, Segal\u00e9s J, Mart\u00edn M, Pujols J, Mateu E. Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infection. Vet Res. 2012, 19:43:30.<\/li>\n
    • Dwivedi V, Manickam C, Binjawadagi B, Linhares D, Murtaugh MP, Renukaradhya GJ. Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. Virol J. 2012, 9:45.<\/li>\n
    • Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine. 2009, 27:3704-18.<\/li>\n
    • Labarque GG, Nauwynck HJ, Van Reeth K, Pensaert MB. Effect of cellular changes and onset of humoral immunity on the replication of porcine reproductive and respiratory syndrome virus in the lungs of pigs. J Gen Virol. 2000, 81:1327-34.<\/li>\n
    • Lopez OJ, Osorio FA. Role of neutralizing antibodies in PRRSV protective immunity. Vet Immunol Immunopathol. 2004, 102:155-63.<\/li>\n
    • Lowe JE, Husmann R, Firkins LD, Zuckermann FA, Goldberg TL. Correlation of cell-mediated immunity against porcine reproductive and respiratory syndrome virus with protection against reproductive failure in sows during outbreaks of porcine reproductive and respiratory syndrome in commercial herds. J Am Vet Med Assoc. 2005, 226:1707-11.<\/li>\n
    • Lunney JK, Benfield DA, Rowland RR. Porcine reproductive and respiratory syndrome virus: an update on an emerging and re-emerging viral disease of swine. Virus Res. 2010, 154:1-6.<\/li>\n
    • Lunney JK, Fang Y, Ladinig A, Chen N, Li Y, Rowland B, Renukaradhya GJ. Porcine reproductive and respiratory syndrome virus (PRRSV): Pathogenesis and Interaction with the Immune System. Annu Rev Anim Biosci. 2016, 4:129-54<\/li>\n
    • Martelli P, Gozio S, Ferrari L, Rosina S, De Angelis E, Quintavalla C, Bottarelli E, Borghetti P. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity. Vaccine. 2009, 27:3788-99.<\/li>\n
    • Mart\u00ednez-Lobo FJ, D\u00edez-Fuertes F, Simarro I, Castro JM, Prieto C. Porcine Reproductive and Respiratory Syndrome Virus isolates differ in their susceptibility to neutralization. Vaccine. 2011, 29:6928-40.<\/li>\n
    • Mateu E, Diaz I. The challenge of PRRS immunology. Vet J. 2008, 177:345-51.<\/li>\n
    • Meier WA, Galeota J, Osorio FA, Husmann RJ, Schnitzlein WM, Zuckermann FA. Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination. Virology. 2003, 309:18-31.<\/li>\n
    • Mengeling WL, Lager KM, Vorwald AC, Koehler KJ. Strain specificity of the immune response of pigs following vaccination with various strains of porcine reproductive and respiratory syndrome virus. Vet Microbiol. 2003, 93:13-24.<\/li>\n
    • Miranda J, Torrents D, Busquet M, Fenech M, Mateu E, D\u00edaz I. Heterologous cell-mediated immune responses against PRRS virus in gilts vaccinated intramuscularly and intradermally with UNISTRAIN\u00ae PRRS. 2015, 7th International Symposium on Emerging and Re-emerging Pig Diseases.<\/li>\n
    • Murtaugh MP, Xiao Z, Zuckermann F. Immunological responses of swine to porcine reproductive and respiratory syndrome virus infection. Viral Immunol. 2002, 15:533-47.<\/li>\n
    • Murtaugh MP, Genzow M. Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS). Vaccine. 2011, 29:8192-204.<\/li>\n
    • Murtaugh MP, Stadejek T, Abrahante JE, Lam TT, Leung FC. The ever-expanding diversity of porcine reproductive and respiratory syndrome virus. Virus Res. 2010, 154:18-30.<\/li>\n
    • Rose N, Renson P, Andraud M, Paboeuf F, Le Potier MF, Bourry O. Porcine reproductive and respiratory syndrome virus (PRRSv) modified-live vaccine reduces virus transmission in experimental conditions. Vaccine. 2015, 33:2493-9.<\/li>\n
    • Pileri E, Gibert E, Soldevila F, Garc\u00eda-Saenz A, Pujols J, Diaz I, Darwich L, Casal J, Mart\u00edn M, Mateu E. Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model. Vet Microbiol. 2015, 175:7-16.<\/li>\n
    • Prieto C, Alvarez E, Mart\u00ednez-Lobo FJ, Simarro I, Castro JM. Similarity of European porcine reproductive and respiratory syndrome virus strains to vaccine strain is not necessarily predictive of the degree of protective immunity conferred. Vet J. 2008, 175:356-63.<\/li>\n
    • Roca M, Gimeno M, Bruguera S, Segal\u00e9s J, D\u00edaz I, Galindo-Cardiel IJ, Mart\u00ednez E, Darwich L, Fang Y, Maldonado J, March R, Mateu E. Effects of challenge with a virulent genotype II strain of porcine reproductive and respiratory syndrome virus on piglets vaccinated with an attenuated genotype I strain vaccine. Vet J. 2012, 193:92-6.<\/li>\n
    • Royaee AR, Husmann RJ, Dawson HD, Calzada-Nova G, Schnitzlein WM, Zuckermann FA, Lunney JK. Deciphering the involvement of innate immune factors in the development of the host response to PRRSV vaccination. Vet Immunol Immunopathol. 2004, 102:199-216.<\/li>\n
    • Scortti M, Prieto C, Mart\u00ednez-Lobo FJ, Simarro I, Castro JM. Effects of two commercial European modified-live vaccines against porcine reproductive and respiratory syndrome viruses in pregnant gilts. Vet J. 2006, 172:506-14.<\/li>\n
    • Weesendorp E, Morgan S, Stockhofe-Zurwieden N, Popma-De Graaf DJ, Graham SP, Rebel JM. Comparative analysis of immune responses following experimental infection of pigs with European porcine reproductive and respiratory syndrome virus strains of differing virulence. Vet Microbiol. 2013, 163:1-12.<\/li>\n
    • Yoon KJ, Wu LL, Zimmerman JJ, Platt KB. Field isolates of porcine reproductive and respiratory syndrome virus (PRRSV) vary in their susceptibility to antibody dependent enhancement (ADE) of infection. Vet Microbiol. 1997, 55:277-87.<\/li>\n
    • Zimmerman JJ, Benfield DA, Dee SA, Murtaugh MP, Stadejek T, Stevenson GW, Torremorell M. Porcine reproductive and respiratory syndrome virus (porcine arterivirus). In: 10th ed. Diseases of swine, Ed. Wiley-Blackwell. 2012, 31:463-86.<\/li>\n<\/ul>\n<\/p><\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n
      <\/div><\/div>","protected":false},"excerpt":{"rendered":"

      [vc_row][vc_column width=\u00bb1\/1″][vc_column_text el_class=\u00bbintro\u00bb]Actualmente, existen alrededor de 30 vacunas, algunas de ellas est\u00e1n disponibles solo en\u00a0su pa\u00eds de origen. Pr\u00e1cticamente todas ellas est\u00e1n basadas en virus atenuado (modified live\u00a0virus; MLV) o en virus inactivado (killed virus; KV) para PRRSV1 o PRRSV2, con la excepci\u00f3n\u00a0de dos vacunas de PRRSV2 basadas en subunidades. A d\u00eda de hoy, las vacunas que m\u00e1s se\u00a0utilizan en el campo son las MLV.[\/vc_column_text][vc_column_text]Desafortunadamente, las vacunas existentes tienen una eficacia limitada, ya que no\u00a0otorgan protecci\u00f3n completa y\/o universal. En general, las vacunas comerciales ofrecen\u00a0una buena protecci\u00f3n cl\u00ednica y virol\u00f3gica frente a un desaf\u00edo gen\u00e9ticamente hom\u00f3logo.\u00a0Sin embargo, su eficacia frente a cepas heter\u00f3logas es muy variable.[\/vc_column_text][vc_column_text]La industria farmac\u00e9utica y los centros de investigaci\u00f3n dedican grandes esfuerzos en\u00a0desarrollar vacunas contra el virus. Sin embargo, las vacunas experimentales (vectores\u00a0recombinantes que expresan prote\u00ednas del virus, vacunas ADN o vacunas basadas en\u00a0subunidades, por nombrar tan s\u00f3lo algunos ejemplos), no son capaces de superar ni las\u00a0estrategias que usa el virus para escapar de la inmunidad ni el inconveniente que supone\u00a0su elevada diversidad gen\u00e9tica. Por tanto, se considera que la eficacia de dichas vacunas\u00a0es como mucho equiparable a las de las MLV.[\/vc_column_text][vc_column_text el_class=\u00bbdestacado\u00bb] Ya sea en una granja concreta o en una regi\u00f3n, el manejo, la […]<\/p>\n","protected":false},"author":19,"featured_media":17056,"parent":20697,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_cbd_carousel_blocks":"[]","yasr_overall_rating":0,"yasr_post_is_review":"","yasr_auto_insert_disabled":"","yasr_review_type":"Product","footnotes":""},"categories":[],"tags":[],"class_list":["post-20676","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yasr_visitor_votes":{"number_of_votes":0,"sum_votes":0,"stars_attributes":{"read_only":false,"span_bottom":false}},"_links":{"self":[{"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/pages\/20676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/comments?post=20676"}],"version-history":[{"count":3,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/pages\/20676\/revisions"}],"predecessor-version":[{"id":20868,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/pages\/20676\/revisions\/20868"}],"up":[{"embeddable":true,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/pages\/20697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/media\/17056"}],"wp:attachment":[{"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/media?parent=20676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/categories?post=20676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prrscontrol.com\/es\/wp-json\/wp\/v2\/tags?post=20676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}